Disclosed is the use of an EpCAMxCD3 bispecific single-chain antibody for the preparation of a pharmaceutical composition for ameliorating and/or preventing a medical condition, mediated by the continued (therapeutic) administration of an EpCAMxCD3 bispecific antibody to a human patient, wherein: (a) a first dose of said antibody is formulated for continuous administration for a first period of time and (b) a second dose of said antibody is formulated for continuous administration for a second consecutive period of time wherein said second dose exceeds said first dose, and wherein said medical condition is characterised by an increase of the serum level of at least one liver enzyme. Also disclosed is a pharmaceutical package or kit comprising a first dose of an EpCAMxCD3 bispecific single-chain antibody formulated for continuous administration for a first period of time, and a second dose of an EpCAMxCD3 bispecific single-chain antibody formulated for continuous administration for a second consecutive period of time, wherein said second dose exceeds said first dose, and wherein said antibody comprises the six CDR sequences of MT110.
